Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Axonics, Inc.
  6. Summary
    AXNX   US05465P1012

AXONICS, INC.

(AXNX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
61.18(c) 59.55(c) 61.58(c) 58.51(c) 54.6 Last
545 654 682 393 334 247 329 999 1 100 594 Volume
+1.78% -2.66% +3.41% -4.99% -6.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 177 M - -
Net income 2021 -80,6 M - -
Net cash position 2021 206 M - -
P/E ratio 2021 -28,9x
Yield 2021 -
Sales 2022 230 M - -
Net income 2022 -58,5 M - -
Net cash position 2022 210 M - -
P/E ratio 2022 -44,3x
Yield 2022 -
Capitalization 2 528 M 2 528 M -
EV / Sales 2021 13,1x
EV / Sales 2022 10,1x
Nbr of Employees 416
Free-Float 88,3%
More Financials
Company
Axonics, Inc., formerly Axonics Modulation Technologies, Inc., is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses... 
More about the company
Ratings of Axonics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AXONICS, INC.
11/17Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Techn..
BU
11/08Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
BU
11/05Needham Adjusts Price Target on Axonics to $71 From $78, Maintains Buy Rating
MT
11/05SVB Leerink Adjusts Price Target on Axonics to $85 from $80, Keeps Outperform Rating
MT
11/04Corporate Presentation
PU
11/04AXONICS : Q3 Earnings Snapshot
AQ
11/04AXONICS, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/04Axonics® Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/04Axonics Q3 Loss Widens, Sales Rise; Cuts Full-Year Revenue Guidance -- Shares Fall Afte..
MT
11/04AXONICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/04Axonics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/04Earnings Flash (AXNX) AXONICS Posts Q3 Revenue $46.9M, vs. Street Est of $48.4M
MT
11/04Axonics® Reports Third Quarter 2021 Financial Results
BU
11/04Axonics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021
CI
10/26Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County
BU
More news
News in other languages on AXONICS, INC.
11/04Axonics creuse sa perte au troisième trimestre, mais augmente son chiffre d'affaires et..
11/04Earnings Flash (AXNX) AXONICS affiche un chiffre d'affaires de 46,9 millions de dollars..
11/04Axonics, Inc. fournit des prévisions de résultats pour le quatrième trimestre et l'anné..
09/23Axonics est convaincue qu'elle n'enfreint aucun brevet de Medtronic malgré la décision ..
09/14Medtronic déclare que l'Office américain des brevets rejette la contestation d'Axonics ..
More news
Analyst Recommendations on AXONICS, INC.
More recommendations
Chart AXONICS, INC.
Duration : Period :
Axonics, Inc. Technical Analysis Chart | AXNX | US05465P1012 | MarketScreener
Technical analysis trends AXONICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 54,60 $
Average target price 77,13 $
Spread / Average Target 41,3%
EPS Revisions
Managers and Directors
Raymond Wayne Cohen Chief Executive Officer & Director
Danny L. Dearen President & Chief Financial Officer
Michael H. Carrel Chairman
Guang Qiang Jiang Chief Technology Officer
Karen Noblett Chief Medical Officer
Sector and Competitors